特立帕肽治疗骨质疏松性骨折的研究进展

Advances in teriparatide-based treatment of osteoporotic fractures

骨质疏松性骨折是骨质疏松症的严重并发症,死亡率及致残率较高,严重影响老年人的身体健康和生活质量。目前骨质疏松性骨折治疗方法主要是外科固定,但骨质疏松症前期缺乏有效的干预手段。特立帕肽是人工合成的甲状旁腺激素的活性片段,是目前唯一促进成骨细胞合成代谢的药物,可以提高骨密度,改善骨重建,已用于骨质疏松症的临床治疗。这个独特优势使其可能为骨质疏松性骨折的治疗提供一种新的方法。因此本文通过介绍骨质疏松性骨折及特立帕肽的作用机制,探讨特立帕肽在骨质疏松性骨折治疗中的应用。

Osteoporotic fracture is a severe complication of osteoporosis, with very high mortality and disability rate, which may significantly deteriorate the health and quality-of-life of elderly patients. Surgical fixation is the main treatment currently. But there is still no effective intervention on early osteoporosis. Teriparatide is a synthetic polypeptide parathyroid hormone, the only drug found so far, can promote bone formation and metabolism. As a result of its unique mechanism of action on bone, it leads to be adopted as the only anabolic therapy for osteoporosis. This unique advantage may provide a new method for treatment of osteoporotic fractures. Thus, the therapeutic mechanism of teriparatide on osteoporotic fractures and its application are introduced in this article.